Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 9;7(5):e2091.
doi: 10.1002/hsr2.2091. eCollection 2024 May.

The effect of duloxetine on stress urinary incontinence

Nahid Lorzadeh  1 , Moghadaseh Jahanshahi  2
Affiliations

The effect of duloxetine on stress urinary incontinence

Nahid Lorzadeh et al. Health Sci Rep. .

Abstract

Background and aims: This study aims to evaluate the effect of duloxetine on stress urinary incontinence (SUI) episode frequency (IEF) per week IEF.

Methods: In this clinical trial, 100 women aged 20-80 years with urinary incontinence were assessed based on the standard questionnaire of urinary tract disorders. All the patients received a placebo for 2 weeks. Patients were then randomly divided into two groups of 50 patients each, receiving duloxetine (40 mg twice a day for 12 weeks) and placebo. The two groups were compared in terms of IEF and the mean score of quality of life and side effects.

Results: The two groups of duloxetine and placebo recipients were matched at the beginning of the study in terms of age, BMI, IEF, parity, and type of delivery. IEF significantly decreased in the duloxetine recipient group compared to the placebo group. The mean score of quality of life in the duloxetine recipient group increased significantly. The rate of study abandonment in the duloxetine recipient group was significantly higher than in the placebo group. Vertigo was the most common complication that caused patients to discontinue the use of the drug.

Conclusion: Duloxetine is therapeutically effective for SUI in women. Patients should be provided information regarding potential side effects and their management.

Keywords: bladder; duloxetine; norepinephrine; placebo; stress urinary incontinence; women.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

References

    1. Vaughan CP, Fitzgerald CM, Markland AD. Management of urinary incontinence in older adults in rehabilitation care settings. Curr Phy Med Rehabilitation Rep. 2019;7(2):159‐169.
    1. McAninch J. Smith's General Urology. McGraw‐Hill Companies; 2008.
    1. Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I‐QOL). Urology. 1999;53(1):71‐76. - PubMed
    1. Tanagho E, McAninch J. Smith's General Urology. McGraw‐Hill Prof Med/Tech; 2007.
    1. Thor KB, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract. 2007;61(8):1349‐1355. - PubMed

LinkOut - more resources